Funder
The author(s) received no specific funding for this work.
Abstract
According to current World Health Organization (WHO) updates, the COVID-19 pandemic has spread all over the globe, affecting 216 countries, and has caused 8,860,331 confirmed cases and 465,740 deaths as of June 24, 2020. Many countries cannot afford nucleic acid tests to confirm COVID-19 infection; as a result, people cannot know the COVID-19 status of the people living around them. The use of dexamethasone in COVID-19 hospitalized patients for up to 10 days lowered 28-day mortality compared to patients receiving standard of care plus mechanical ventilation at randomization (by 12.3 age-adjusted percentage points, approximately one-third of proportional reduction) and patients receiving oxygen without invasive mechanical ventilation (by 4.1 age-adjusted percentage points, approximately one-fifth of proportional reduction).
DOI
10.18297/jri/vol4/iss1/66
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Khan, Muhammad Arif; Ullah, Ikram; and Ahmed, Dawood
(2020)
"COVID-19 and the Unseen Benefits of Dexamethasone,"
The University of Louisville Journal of Respiratory Infections: Vol. 4
:
Iss.
1
, Article 66.
DOI: https://doi.org/10.18297/jri/vol4/iss1/66
Available at:
https://ir.library.louisville.edu/jri/vol4/iss1/66
